A.A. Luczak

653 total citations
11 papers, 45 citations indexed

About

A.A. Luczak is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, A.A. Luczak has authored 11 papers receiving a total of 45 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 4 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in A.A. Luczak's work include HER2/EGFR in Cancer Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and CAR-T cell therapy research (4 papers). A.A. Luczak is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and CAR-T cell therapy research (4 papers). A.A. Luczak collaborates with scholars based in Denmark, Spain and Türkiye. A.A. Luczak's co-authors include Mateo Sokač, Boe Sandahl Sørensen, Martin R. Jakobsen, Ninna Aggerholm‐Pedersen, Nicolai J. Birkbak, Jesper Pedersen, Bent Ejlertsen, Peter Michael Vestlev, Erik Jakobsen and Sven Tyge Langkjer and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Breast Cancer Research and Treatment.

In The Last Decade

A.A. Luczak

8 papers receiving 45 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A.A. Luczak Denmark	4	38	18	13	11	6	11	45
Baohui Han China	5	31 0.8×	26 1.4×	7 0.5×	6 0.5×	6 1.0×	8	43
Yuko Tanabe Japan	3	35 0.9×	17 0.9×	13 1.0×	9 0.8×	11 1.8×	6	46
Livia Andrade United States	2	69 1.8×	31 1.7×	21 1.6×	24 2.2×	4 0.7×	3	76
Spartak Valev Bulgaria	3	47 1.2×	20 1.1×	9 0.7×	10 0.9×	9 1.5×	6	69
Regina Mendrzyk United States	4	33 0.9×	26 1.4×	16 1.2×	13 1.2×	18 3.0×	6	46
Jaya Thomas United Kingdom	3	23 0.6×	6 0.3×	17 1.3×	9 0.8×	9 1.5×	6	38
Jessica Waninger United States	6	38 1.0×	13 0.7×	21 1.6×	10 0.9×	19 3.2×	12	64
Natalia Valdiviezo Peru	5	33 0.9×	28 1.6×	5 0.4×	9 0.8×	12 2.0×	16	50
Julie S. Deutsch United States	5	26 0.7×	21 1.2×	8 0.6×	4 0.4×	12 2.0×	9	43
Blanca Ledezma United States	5	49 1.3×	17 0.9×	12 0.9×	7 0.6×	7 1.2×	11	52

Countries citing papers authored by A.A. Luczak

Since Specialization

Citations

This map shows the geographic impact of A.A. Luczak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.A. Luczak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.A. Luczak more than expected).

Fields of papers citing papers by A.A. Luczak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.A. Luczak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.A. Luczak. The network helps show where A.A. Luczak may publish in the future.

Co-authorship network of co-authors of A.A. Luczak

This figure shows the co-authorship network connecting the top 25 collaborators of A.A. Luczak. A scholar is included among the top collaborators of A.A. Luczak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.A. Luczak. A.A. Luczak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Khan, Shaheen, Pernille Envold Bidstrup, Karina Dahl Steffensen, et al.. (2025). Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage IIIA-D melanoma patients. 3. 100553–100553.

Donia, Marco, Kasper Madsen, Henrik Schmidt, et al.. (2025). Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma. European Journal of Cancer. 221. 115402–115402.

Mirza, Mansoor R., Line Bjørge, Frederik Marmé, et al.. (2024). Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. Gynecologic Oncology. 192. 128–136. 3 indexed citations

Kisistók, Judit, Mads H. Rasmussen, Ninna Aggerholm‐Pedersen, et al.. (2023). Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel. Melanoma Research. 33(5). 364–374. 2 indexed citations

Pedersen, Jesper, Mateo Sokač, Boe Sandahl Sørensen, et al.. (2022). Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma. Cancers. 14(14). 3342–3342. 18 indexed citations

Bastholt, Lars, Inge Marie Svane, Marco Donia, et al.. (2021). Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers. 13(21). 5550–5550. 3 indexed citations

Brems-Eskildsen, Anne Sofie, Søren Linnet, Hella Danø, et al.. (2020). Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer. Acta Oncologica. 60(2). 157–164. 9 indexed citations

Christensen, Ib Jarle, Eva Balslev, Ann Knoop, et al.. (2019). Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay. Breast Cancer. 27(2). 266–276. 1 indexed citations

Christensen, Ib Jarle, Eva Balslev, Ann Knoop, et al.. (2018). Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study. Breast Cancer Research and Treatment. 172(2). 391–400. 5 indexed citations

10.

Ejlertsen, Bent, Carlos H. Barrios, Erhan Gökmen, et al.. (2018). Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.. Journal of Clinical Oncology. 36(15_suppl). 549–549. 4 indexed citations

11.

Brems-Eskildsen, Anne Sofie, A.A. Luczak, Peter Michael Vestlev, et al.. (2015). Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients. Repositorio Institucional E-DocUR (Universidad Del Rosario). 23.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact